RxDoctor Payments Data

Alyssa Mosley

Physician Assistant · Sacramento, CANPI 1215662739

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.6% of the total across 339 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,357, 9.5 times the $456 reported in 2022. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,933in general payments, 2019–2025

Across 339 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$838
  • AstraZeneca$748
  • Pfizer$740
  • Johnson & Johnson$710
  • Astellas Pharma US Inc$482
  • Lilly USA, LLC$469
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$7,42494%
  • Education$5106%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,933 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California →

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$19,791
JardianceEmpagliflozin11$13,020
OzempicSemaglutide13$12,638
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,576
FarxigaDapagliflozin Propanediol16$10,438
Atorvastatin Calcium85$1,290
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen70$1,143
Gabapentin47$1,091
Metoprolol Succinate32$993
Albuterol Sulfate HfaAlbuterol Sulfate37$916
Duloxetine Hcl16$810
Estradiol16$754
Losartan Potassium51$691
Amlodipine Besylate46$545
Pantoprazole Sodium30$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$838$19,79112 claims
Boehringer IngelheimJardiance$224$13,02011 claims
Novo NordiskOzempic$331$12,63813 claims
GSKTrelegy Ellipta$139$12,57621 claims
AstraZenecaFarxiga$748$10,43816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Sacramento

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →